Pharmaceutical Costs

When states pass laws designed to control prescription drug costs, the pharmaceutical industry often responds with lawsuits claiming states are hindering interstate commerce and violating the federal Dormant Commerce Clause (DCC). NASHP’s legal experts believe states can craft drug cost policies that can withstand industry challenges. This brief by Anna Zaret and Darien Shankse provides insight and […]

Read More
  • How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs
    State Health Policy Blog

    New state laws designed to control the costs of brand-name and generic prescription drugs often face legal challenges from the pharmaceutical industry. These lawsuits can vary depending on the individual state law, but recent industry lawsuits analyzed by the National Academy for State Health Policy (NASHP) share a common legal thread – drug manufacturers and […]

    Read More
  • Utah’s Norman Thurston Takes a Red State Approach to Lower Rx Costs with a Bill to Import Drugs from Canada
    State Health Policy Blog

    For more than a decade, Utah State Legislator and Director of the Office of Health Care Statistics Norman Thurston has worked to reform his state’s health care system, including its Medicaid program, and is considered one of the state’s “go-to” health care policymakers. Thurston, a Republican, has worked to reduce state spending on prescription drugs and […]

    Read More
  • NASHP Awards Grants to Colorado, Delaware, and Oklahoma to Tackle Rising Rx Drug Prices
    State Health Policy Blog

    The National Academy for State Health Policy (NASHP) has awarded $300,000 in grants to Colorado, Delaware, and Oklahoma to help the states develop innovative policy solutions to tackle high prescription drug prices. With the support from the Laura and John Arnold Foundation, the funding enables states to explore promising policy approaches to control rapidly escalating […]

    Read More
  • Lowering Drug Costs: Transparency Legislation Sets Off Flurry of New State Approaches
    State Health Policy Blog

    Responding to rapidly rising drug costs, 30 states across the country have drafted more than 60 drug price transparency bills designed to: Identify the costs that contribute to drug manufacturer expenses and list prices And unveil the often opaque business practices of pharmacy benefit managers (PBMs). In addition to promoting pricing transparency, as of early […]

    Read More
  • State Health Policy Blog

    States are searching for new and innovative approaches to handle the rising cost of prescription medicines – both the sudden spike in spending that comes with a new high-cost treatment and the ongoing challenges of regular, inexplicable, price hikes for all covered drugs. The United States has the highest prescription drug prices in the world. […]

    Read More
  • The National Academy for State Health Policy (NASHP), with support from the Laura and John Arnold Foundation, today launched the Center for State Rx Drug Pricing. Building on the work of the Pharmacy Costs Work Group, the Center will provide technical and strategic assistance to states, leverage legal and actuarial expertise as needed, distribute funding […]

    Read More
    June 20, 2017 | Filed under: Front Page-Rx, Pharmaceutical Costs, Prescription Drugs
  • State Health Policy Blog

    In its May 30, 2017 decision Impression Products, Inc. v Lexmark International Inc., the Supreme Court ruled that patent law cannot be used to prevent the resale of products back into the United States. The Court case specifically concerned printer toner cartridges, but it is an important ruling in the context of the domestic policy […]

    Read More
  • As States Wage Battles on High Drug Prices, Drugmakers Fight Back May 18, 2017 Lembo targets ‘skyrocketing’ drug prices January 24, 2017 How can states tackle rising medication prices? January 11, 2017 Interfaith investor coalition pushes shareholder resolutions on drug prices, October 24, 2016 Politico Pulse mentioned the findings of the Pharmacy Costs Work Group, October 24, 2016 […]

    Read More
  • Publications

    Because the federal government has not been able to agree on an approach to constrain prescription drug prices, states need to address the problem. Study after study show how U.S. consumers pay the highest prices in the world for life-saving and life-enhancing drug treatments. The prices we pay may fund the research and development that […]

    Read More